Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics

Madrigal Pharmaceuticals, Inc. (MDGL): $73.59

2.01 (+2.81%)

POWR Rating

Component Grades













MDGL Stock Price Chart Interactive Chart >

Price chart for MDGL

MDGL Price/Volume Stats

Current price $73.59 52-week high $105.93
Prev. close $71.58 52-week low $52.33
Day low $71.43 Volume 133,600
Day high $74.17 Avg. volume 215,674
50-day MA $69.96 Dividend yield N/A
200-day MA $80.05 Market Cap 1.26B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.

MDGL Latest News Stream

Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream

Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals Q4 net loss widens Y/Y

Madrigal Pharmaceuticals (NASDAQ:MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The company said the decreases in interest income for Q4 and FY 2021 was mainly due to lower average principal balances in...

Seeking Alpha | February 24, 2022

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “2021 was a year of significant progress for Madrigal as we continued to advance our industry-leadi

Yahoo | February 24, 2022

VKTX, FRSX and SEAC among pre market gainers

Madrigal Pharmaceuticals MDGL +15% liver disease candidate improved key patient outcomes in late-stage study.Yoshitsu Co (TKLF) +14%

Seeking Alpha | January 31, 2022

Why Madrigal Pharmaceuticals Stock Briefly Spiked Today

Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by as much as 18% in pre-market action Monday morning. The gains came in response to a positive top-line readout from a phase 3 clinical trial for resmetirom, its experimental fatty liver disease drug candidate. Madrigal said that the drug was safe and well-tolerated at both the 80 mg and 100 mg dose levels assessed in the trial.

Yahoo | January 31, 2022

Madrigal shares rise, market cap surpasses $1B on positive late-stage study results for lead drug candidate

Founded in 2011, the Conshohocken company has grown to about 50 employees and is led by the husband-and-wife team.

Yahoo | January 31, 2022

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo 2.72%
3-mo -21.36%
6-mo -10.16%
1-year -25.67%
3-year -27.60%
5-year 350.92%
YTD -13.16%
2021 -23.77%
2020 22.02%
2019 -19.17%
2018 22.80%
2017 516.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5009 seconds.